Journals / Haydarpaşa Numune Medical Journal / 2019 / Cilt: 59 - Sayı: 2

Gastrointestinal Stromal Tumors: Retrospective Analysis of 21 Cases

Pages
157–161
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The goal of surgery is complete gross resection with an intact pseudocapsule and negative microscopic margins.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract.
📊
Key Findings & Data:The aim of this study was to evaluate 21 patients operated for GIST.
💡
Conclusion & Impact:The goal of surgery is complete gross resection with an intact pseudocapsule and negative microscopic margins.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Özet

Introduction: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract. The aim of this study was to evaluate 21 patients operated for GIST. Methods: We retrospectively analyzed medical and surgical records of 21 patients diagnosed with GIST who were operated between 2008 and 2014 in our clinic. Gastrointestinal stromal tumors localizations, applied surgical methods, histopathological examination results, postoperative medical treatments, and follow-up results were examined. Results: The study group consisted of 21 patients (11 males and 10 females) with a mean age of 69.29 (range, 39–89 years). Sixteen tumors were located in the stomach, 3 in the small intestine, 1 in the rectum, and 1 in the mesentery of the jejunum. The symptoms were not typical, and they depended on the localization and size of the tumor. The mean tumor size was 6.8 cm (range, 1.8–20 cm). Positivity rates for CD117 and CD34 expression determined by immunohistochemical methods were 95.2%, and 66.7%, respectively. One patient underwent laparoscopic resection, and other patients were treated via open surgery. Lymph node metastasis was observed in the patient with rectal tumor. Postoperatively, imatinib therapy was administered in 5 patients with high-risk tumors. Mortality was observed in 2 patients. Four patients were excluded from the follow-up because they could not be reached by phone. The mean follow-up period was 29.59±15.4 months. No recurrences or metastases have been detected. Discussion and Conclusion: Gastrointestinal stromal tumors represent 0.1%–1% of all gastrointestinal malignancies. The most common location is the stomach. The goal of surgery is complete gross resection with an intact pseudocapsule and negative microscopic margins.

🔖

Cite This Article

ATAK, T., EREN, T. T., BURCU, B., SAĞIROĞLU, J., ÖZEMİR, İ. A., ALİMOĞLU, O. (2019). Gastrointestinal Stromal Tumors: Retrospective Analysis of 21 Cases. Haydarpaşa Numune Medical Journal, Cilt: 59 - Sayı: 2, 157–161. https://ajindex.com/articles/190430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8 Suppl 2:S1–41. [CrossRef ] 2. Bilgen K, Hasçiçek SC, Çetinkünar S, Celep B, Tokgöz S, Tunç G, et al. Atlı. Gastrointestinal Stromal Tümörlerde Prognostik Faktörler. Yeni Tıp Dergisi 2011;28:95–9. 3. Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal tumor. Surg Oncol 2008;17:129–38. [CrossRef ] 4. Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am 2009;89:217–33. [CrossRef ] 5. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259–69. 6. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al.; GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566–78. 7. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–9. [CrossRef ] 8. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705–12. [CrossRef ] 9. Sakamoto Y, Yamamoto J, Takahashi H, Kokudo N, Yamaguchi T, Muto T, et al. Segmental resection of the third portion of the duodenum for a gastrointestinal stromal tumor: a case report. Jpn J Clin Oncol 2003;33:364–6. [CrossRef ] 10. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459–65. [CrossRef ] 11. Folgado Alberto S, Sánchez P, Oliveira M, Cuesta L, Gomes F, Figueiredo A, et al. Gastrointestinal stromal tumors - a retrospective study of 43 cases. [Article in Spanish]. Rev Esp Enferm Dig 2008;100:696–700. [CrossRef ] 12. Boldorini R, Tosoni A, Leutner M, Ribaldone R, Surico N, Comello E, et al. Multiple small intestinal stromal tumours in a patient with previously unrecognised neurofibromatosis type 1: immunohistochemical and ultrastructural evaluation. Pathology 2001;33:390